Bayer AG NA Risks

Key risks and downside factors

Bayer AG operates across three markets: pharmaceuticals (specialty medicines and oncology), crop science (seeds, traits and crop-protection), and consumer health. Its most relevant competitors are major global pharma groups—Pfizer, Novartis, Roche, AstraZeneca, Merck—and large agricultural players including Corteva, Syngenta, BASF, and FMC. In consumer health, it competes with Haleon, Kenvue, Reckitt, and Perrigo. The company faces material litigation and regulatory risk tied to Roundup and glyphosate, alongside pipeline pressures and patent expirations. Its Crop Science division remains exposed to commodity and crop-demand cycles.

• Ongoing litigation and settlements related to glyphosate expose Bayer to material cash outflows, potential operational constraints, and reputational risk, based on active cases and recent settlement activity the company has disclosed.
• Pharmaceutical pipeline and patent expiry risk: if exclusivity lapses or new drug launches underperform expectations, margins and growth could lag behind larger specialty competitors.
• Crop science companies face exposure to commodity price fluctuations, weather patterns, and regulatory shifts—particularly around pesticide approvals and seed trait regulations—that can quickly reshape both demand and product availability.
• Integration, portfolio, and capital-allocation risk—including restructuring or asset separations designed to isolate liabilities, such as recent moves to separate U.S. glyphosate assets—and their potential impact on cash flow and credit metrics.